EARLY-STAGE MMR-DEFICIENT ENDOMETRIAL CANCER

Clinical trials for EARLY-STAGE MMR-DEFICIENT ENDOMETRIAL CANCER explained in plain language.

Never miss a new study

Get alerted when new EARLY-STAGE MMR-DEFICIENT ENDOMETRIAL CANCER trials appear

Sign up with your email to follow new studies for EARLY-STAGE MMR-DEFICIENT ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug combo aims to save wombs in young women with uterine cancer

Disease control Recruiting now

This study tests a combination of an immune-boosting drug (TQB2450) and a high-dose hormone (progestin) to treat young women (ages 18-45) with a specific type of early-stage endometrial cancer (MMRd). The goal is to eliminate the cancer while preserving the uterus so patients can…

Matched conditions: EARLY-STAGE MMR-DEFICIENT ENDOMETRIAL CANCER

Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control

Last updated Jun 17, 2026 12:03 UTC

EARLY-STAGE MMR-DEFICIENT ENDOMETRIAL CANCER

Get alerted when new EARLY-STAGE MMR-DEFICIENT ENDOMETRIAL CANCER trials appear

New drug combo aims to save wombs in young women with uterine cancer